Congenica’s Saudi springboard to Middle East growth
Cambridge-based digital health company Congenica has become a major influencer in the sector across the Middle East.
The company, based at the Wellcome Sanger Institute, drives precision medicine by enabling the rapid analysis and interpretation of genomic data at scale.
It has just announced a strategic partnership with NoorDx, an innovative clinical genomics and research services company located at the KAUST Innovation Cluster in the Kingdom of Saudi Arabia (KSA).
The new partnership, which has already secured interest from major healthcare providers across the Middle East, will further enable NoorDx to offer customers a fully accredited sample-to-report-service.
This includes analysis and clinical interpretation of sequencing data via its cutting-edge genomics lab, licensed geneticists and Congenica’s Clinical Interpretation Services.
Alistair Johnson, Chief Professional Services Officer at Congenica, said: “We are pleased to announce this partnership with NoorDx, a renowned sequencing facility which shares our commitment to healthcare providers in delivering life-changing answers through the provision of high-quality services and solutions. We look forward to working with NoorDx to deliver the best-in-class support to their customers across the Middle East.”
Dr Dillon Fritz, CEO and co-founder at NoorDx, added: “The partnership between Congenica and NoorDx will further accelerate our mission to fully localise the holistic value chain of clinical genomics in the region, and allow for downstream innovation from both companies to integrate and address the precision medicine need in KSA and beyond.
“Congenica’s pioneering genetic analysis and interpretation technology, coupled with their expert team of registered clinical scientists, will create an optimal synergy with NoorDx’s internationally accredited clinical lab and our portfolio of genomic-based solutions.”